Michael Brooks
Presently, Michael Brooks is President for Edesa Biotech, Inc.
In the past he held the position of Director-Business Development at Cipher Pharmaceuticals, Inc. and President of Edesa Biotech, Inc. (Old).
He received an undergraduate degree and a doctorate from the University of Toronto and an MBA from Rotman School of Management.
Transactions
11/02/2022 | 4,239 | 4,747 | |
11/02/2022 | 4,239 | Award at $1.12 per share. | 4,747 |
06/29/2022 | 3,000 | Acquisition at $1.49 per share. | 4,470 |
06/16/2022 | 3,000 | Acquisition at $1.61 per share. | 4,830 |
05/25/2022 | 3,500 | 6,090 | |
05/25/2022 | 3,500 | Acquisition at $1.74 per share. | 6,090 |
03/14/2022 | 1,250 | 3,487 | |
03/14/2022 | 1,250 | 3,487 | |
03/14/2022 | 1,250 | Acquisition at $2.79 per share. | 3,487 |
03/10/2022 | 1,000 | 3,220 | |
03/10/2022 | 1,000 | 3,220 | |
03/10/2022 | 1,000 | Acquisition at $3.22 per share. | 3,220 |
03/08/2022 | 1,250 | 3,625 | |
03/08/2022 | 1,250 | 3,625 | |
03/08/2022 | 1,250 | Acquisition at $2.9 per share. | 3,625 |
03/25/2021 | 3,500 | 18,165 | |
03/25/2021 | 3,500 | 18,165 | |
03/25/2021 | 3,500 | Acquisition at $5.19 per share. | 18,165 |
03/24/2021 | 4,500 | 22,860 | |
03/24/2021 | 4,500 | 22,860 | |
03/24/2021 | 4,500 | Acquisition at $5.08 per share. | 22,860 |
11/06/2020 | 914 | 3,656 | |
11/06/2020 | 914 | 3,656 | |
11/06/2020 | 914 | 3,656 | |
05/27/2020 | 1,000 | 3,000 | |
05/27/2020 | 1,000 | 3,000 | |
05/27/2020 | 1,000 | Acquisition at $3 per share. | 3,000 |
05/27/2020 | 1,500 | 4,500 | |
05/27/2020 | 1,500 | 4,500 | |
05/27/2020 | 1,500 | Acquisition at $3 per share. | 4,500 |
01/08/2020 | 1,827 | 7,508 | |
01/08/2020 | 1,827 | 7,508 | |
01/08/2020 | 1,827 | 7,508 | |
01/08/2020 | 1,827 | 7,508 | |
01/08/2020 | 1,827 | 7,508 | |
01/08/2020 | 1,827 | 7,508 | |
01/08/2020 | 1,827 | Award at $4.11 per share. | 7,508 |
01/08/2020 | 1,827 | Acquisition at $4.11 per share. | 7,508 |
06/07/2019 | 0 | 0 | |
06/07/2019 | 0 | 0 |